What are the recommended treatment options and follow‑up strategies for meningioma based on tumor size, symptomatology, growth, and patient factors?

Meningioma: Treatment and Follow-Up Recommendations

For WHO grade 1 meningiomas, observation with serial MRI is appropriate for small (<2 cm), asymptomatic tumors, while gross total resection remains the definitive treatment for symptomatic or growing lesions; stereotactic radiosurgery (12-15 Gy single fraction) is an evidence-based alternative for surgically inaccessible tumors, achieving 71-100% 10-year local control. 1

Treatment Strategy by Clinical Scenario

Observation ("Watch-and-Scan")

• Small asymptomatic meningiomas (<2 cm diameter) rarely progress to cause symptoms over 5 years and should be observed with serial imaging. 2
• Tumors between 2-2.5 cm that grow >10% per year have a 42% risk of symptom progression versus 0% for those growing ≤10% per year, making growth rate the critical decision point. 2
• Elderly patients (≥70 years) and those with calcified tumors demonstrate significantly slower growth rates and are ideal candidates for conservative management. 3
• Observation is particularly appropriate for incidentally discovered meningiomas in elderly or asymptomatic patients. 4, 5

Surgical Resection

• Gross total resection including involved dura is the treatment of choice and is potentially curative for WHO grade 1 meningiomas. 1
• Surgery is indicated when tumors cause symptoms, demonstrate significant growth on serial imaging, or are located in areas where growth would cause critical neurological compromise. 4
• Subtotal resection results in lower long-term local control, particularly for skull base tumors where complete removal risks neurovascular injury. 1
• Firmer tumor consistency (Zada types 4-5) correlates with longer operative times (492 vs 382 minutes), higher subtotal resection rates (58.6% vs 15%), and worse progression-free survival. 6

Stereotactic Radiosurgery (SRS)

• SRS is recommended as an effective evidence-based treatment option (Level II recommendation) for WHO grade 1 meningiomas that are surgically inaccessible or in patients who decline surgery. 1
• Prescription dose typically ranges 12-15 Gy delivered in a single fraction. 1
• 10-year local control rates range from 71-100% with 10-year progression-free survival of 55-97%. 1
• Toxicity rates are generally low, making SRS suitable for tumors near critical neurovascular structures. 1
• SRS can be used as primary monotherapy or as adjuvant treatment following subtotal resection. 4, 5

Fractionated Radiotherapy

• Fractionated stereotactic radiotherapy (SRT) is delivered over 5-6 weeks at 1.8-3.0 Gy per fraction for larger tumors or those near dose-limiting organs at risk. 1
• Hypofractionated stereotactic radiotherapy (HSRT) delivers ≤5 fractions at ≥5 Gy per fraction using frameless image-guided systems. 1

Follow-Up Surveillance by WHO Grade

WHO Grade 1 Meningiomas

• MRI brain without and with IV contrast every 6-12 months is the surveillance standard. 1
• Combined histologic and molecular profiling optimizes the frequency of imaging follow-up. 1
• The post-radiotherapy MRI serves as the "new baseline" rather than the post-surgical MRI. 1

WHO Grade 2 and 3 Meningiomas

• More frequent follow-up is required, particularly after treatment, to monitor for pseudoprogression and radiation necrosis. 1
• DOTATATE PET/CT provides more accurate delineation of resection extent and is a useful adjunct for WHO grade 2 and 3 tumors, including assessment of radiotherapy response. 1
• Somatostatin analog PET should be reserved for new findings on surveillance MRI after gross total resection has been confirmed. 1
• For recurrent atypical meningiomas, treatment plans must consider prior radiotherapy exposure, with PET-guided planning and molecular-based risk stratification enabling personalized approaches. 7

Advanced Imaging Considerations

MRI Characteristics

• Typical features include homogeneous dural-based enhancement, dural tail sign, and CSF cleft between tumor and brain. 1
• Intratumoral calcifications visible on susceptibility-weighted imaging (SWI) predict slower growth. 1, 3
• Vasogenic edema on T2 FLAIR correlates with specific histologic subtypes (angiomatous, secretory) but does not reliably predict WHO grade. 1
• T2-weighted signal intensity ratios >1.547 predict softer tumors with 95% sensitivity, while ratios <0.6533 predict firm tumors. 6

PET Imaging

• [¹⁸F]SiTATE PET/CT using an SUV threshold of 4.0 accurately captures meningioma volume in 84% of lesions, though very small lesions (SUVmax <4.2) may be missed. 8
• CT imaging is not recommended for routine surveillance in patients with known meningioma. 1

Critical Pitfalls to Avoid

• Do not assume all meningiomas require immediate intervention—most small asymptomatic tumors can be safely observed. 2, 3
• Do not rely solely on tumor size—growth rate and patient age are equally important prognostic factors. 2, 3
• Beware of meningioma mimics: marked T2-hypo- or hyperintensity, absence of dural tail, and dural displacement sign should raise suspicion. 1
• Brain-invasive meningiomas show upregulation of KRT18, PDGFRB, and increased tumor-associated macrophage infiltration at the brain-meningioma border, warranting closer surveillance. 9